BRVE
NASDAQ HealthcareBraveheart Bio, Inc. - Common Stock
Biotechnology
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
๐ Market Data
| Price | $21.19 |
|---|---|
| Volume | 304,125 |
| Market Cap | 1.91B |
| RSI (14-Day) | 59.2 |
| 50-Day MA | $23.64 |
| 52-Week High | $32.00 |
| 52-Week Low | $17.86 |
| Forward P/E | -10.65 |
| Price / Book | -1.67 |
๐ฏ Investment Strategy Scores
BRVE scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (56/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (7/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find BRVE in your text
Paste any article, transcript, or post โ the tool will extract BRVE and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.